Phase 1 study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis

被引：0
|
作者：
Hamid, Omid [1 ]
Weise, Amy [2 ]
Lewis, Karl D. [3 ]
Kim, Tae Min [4 ]
McKean, Meredith [5 ]
Lakhani, Nehal J. [6 ]
Kaczmar, John [7 ]
Papadopoulos, Kyriakos P. [8 ]
Chen, Shuquan [9 ]
Mani, Jayakumar [9 ]
Gullo, Giuseppe [9 ]
机构：
[1] Cedars Sinai Affiliate, Angeles Clin & Res Inst, Los Angeles, CA USA
[2] Henry Ford Hosp, Detroit, MI USA
[3] Univ Colorado, Denver Canc Ctr, Aurora, CO USA
[4] Seoul Natl Univ Hosp, Seoul, South Korea
[5] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA
[6] START Midwest, Grand Rapids, MI USA
[7] Hollings Canc Ctr, Charleston, SC USA
[8] START San Antonio, San Antonio, TX USA
[9] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
43001
引用
收藏
页码：AB207 / AB207
页数：1
相关论文
共 50 条
  • [41] Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis.
    Hamid, Omid
    Lewis, Karl D.
    Weise, Amym.
    McKean, Meredith
    Papadopoulos, Kyriakos P.
    Crown, John
    Thomas, Sajeve Samuel
    Girda, Eugenia
    Kaczmar, John M.
    Kim, Kevin B.
    Lakhani, Nehal
    Yushak, Melinda Lynne
    Mani, Jayakumar
    Fang, Fang
    Brennan, Laura
    Jankovic, Vladimir
    Paccaly, Anne Josee
    Masinde, Sheila
    Lowy, Israel
    Gullo, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3):: role of LAG-3/MHC class II interactions in cell-cell contacts
    Demeure, CE
    Wolfers, J
    Martin-Garcia, N
    Gaulard, P
    Triebel, F
    EUROPEAN JOURNAL OF CANCER, 2001, 37 (13) : 1709 - 1718
  • [43] Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti-PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations
    Ascierto, P. A.
    Bono, P.
    Bhatia, S.
    Melero, I.
    Nyakas, M. S.
    Svane, I-M.
    Larkin, J.
    Gomez-Roca, C.
    Schadendorf, D.
    Dummer, R.
    Marabelle, A.
    Hoeller, C.
    Maurer, M.
    Harbison, C. T.
    Mitra, P.
    Suryawanshi, S.
    Thudium, K.
    Munoz Couselo, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [44] A Phase 2/3 Study of Fianlimab plus Cemiplimab versus Cemiplimab in Patients with Advanced NSCLC with Tumors Expressing PD-L1 ≥50%
    Faulkner, Neil
    Nair, Santosh
    Gabrail, Nashat
    Kunta, Gopal
    Ibrahim, Emad
    Dreisbach, Luke
    Brungs, Daniel
    Mani, Jayakumar
    Ghattas, Maria
    Li, Siyu
    Salvati, Mark
    Lowy, Israel
    Hiley, Tara
    Fury, Matthew G.
    Paoluzzi, Luca
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E39 - E39
  • [45] Molecular characterization of the lymphocyte activation gene-3 (LAG-3, CD223) of swamp- and riverine-type water buffaloes (Bubalus bubalis)
    Rivera, Shanemae M.
    Padiernos, Ryan Bismark C.
    Abella, Evaristo A.
    Konnai, Satoru
    Mingala, Claro N.
    JAPANESE JOURNAL OF VETERINARY RESEARCH, 2017, 65 (02) : 65 - 74
  • [46] Analysis of LAG-3 expression in metastatic melanoma patients treated with combination anti-LAG-3+anti-PD-1-based immunotherapies
    Gide, T. N.
    Paver, E.
    Yaseen, Z.
    Menzies, A. M.
    Wilmott, J. S.
    Scolyer, R. A.
    Long, G. V.
    HISTOPATHOLOGY, 2022, 81 : 54 - 54
  • [47] Opposite role for interleukin-4 and interferon-gamma on CD30 and lymphocyte activation gene-3 (LAG-3) expression by activated naive T cells
    Annunziato, F
    Manetti, R
    Cosmi, L
    Galli, G
    Heusser, CH
    Romagnani, S
    Maggi, E
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (09) : 2239 - 2244
  • [48] Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway
    Di Carlo, E
    Cappello, P
    Sorrentino, C
    D'Antuono, T
    Pellicciotta, A
    Giovarelli, M
    Forni, G
    Musiani, P
    Triebel, F
    JOURNAL OF PATHOLOGY, 2005, 205 (01): : 82 - 91
  • [49] A phase 3 trial of fixed dose combinations of fianlimab (anti-LAG-3) + cemiplimab (anti-PD-1) versus relatlimab plus nivolumab in patients with unresectable or metastatic melanoma
    Khushalani, Nikhil I.
    Mani, Jayakumar
    Booth, Jocelyn
    Zhang, Zoe
    Salvati, Mark
    Lowy, Israel
    Fury, Matthew G.
    Lewis, Karl
    Manvelian, Garen
    Tawbi, Hussein A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] A phase 3 trial comparing fianlimab (anti-LAG-3) plus cemiplimab (anti-PD-1) to pembrolizumab in patients with completely resected high-risk melanoma.
    Panella, Timothy J.
    Thomas, Sajeve Samuel
    McKean, Meredith
    Margolin, Kim Allyson
    Weight, Ryan Michael
    Mani, Jayakumar
    Patel, Shraddha
    Desai, Priya
    Salvati, Mark
    Lowy, Israel
    Fury, Matthew G.
    Gullo, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345